Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab
BackgroundTo demonstrate the rare ocular side effects in a patient receiving pembrolizumab and nivolumab for metastatic ovarian cancer.Case presentationA 37-year-old woman with recurrent metastatic ovarian cancer presented with blurred vision and photophobia after receiving pembrolizumab. Ocular fin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2022.1021574/full |
| _version_ | 1797960347239317504 |
|---|---|
| author | Wan-Hua Cho Wei-Yu Chiang |
| author_facet | Wan-Hua Cho Wei-Yu Chiang |
| author_sort | Wan-Hua Cho |
| collection | DOAJ |
| description | BackgroundTo demonstrate the rare ocular side effects in a patient receiving pembrolizumab and nivolumab for metastatic ovarian cancer.Case presentationA 37-year-old woman with recurrent metastatic ovarian cancer presented with blurred vision and photophobia after receiving pembrolizumab. Ocular findings were bilateral anterior chamber reactions, iris cysts, and macular flecks. Optical coherence tomography (OCT) indicated retinal pigment epithelium (RPE) and ellipsoid-band disruption. Her symptoms subsided with topical steroids but fundal appearance persisted despite cessation of immunotherapies. Similar episodes attacked again with multiple exudative subretinal fluid (SRF) developed after she received pembrolizumab and nivolumab. Steroids could cease anterior chamber reactions while SRF only subsided after discontinuation of immunotherapy. Extensive RPE and ellipsoid-band disruption remained without vision improvements.ConclusionsWe report a rare case of uveitis and retinopathy after immunotherapies with sequent pembrolizumab and nivolumab. A serial change of the maculopathy is demonstrated. Possible ocular toxicities during the treatment course should be considered, and the benefits of continuing the immunotherapy must be weighed against the risks. |
| first_indexed | 2024-04-11T00:45:38Z |
| format | Article |
| id | doaj.art-4ffc5643f64a45b596ba7cad06a9241e |
| institution | Directory Open Access Journal |
| issn | 2674-0826 |
| language | English |
| last_indexed | 2024-04-11T00:45:38Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Ophthalmology |
| spelling | doaj.art-4ffc5643f64a45b596ba7cad06a9241e2023-01-05T17:25:52ZengFrontiers Media S.A.Frontiers in Ophthalmology2674-08262023-01-01210.3389/fopht.2022.10215741021574Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumabWan-Hua Cho0Wei-Yu Chiang1Department of Ophthalmology, Chi Mei Medical Center, Tainan, TaiwanDepartment of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanBackgroundTo demonstrate the rare ocular side effects in a patient receiving pembrolizumab and nivolumab for metastatic ovarian cancer.Case presentationA 37-year-old woman with recurrent metastatic ovarian cancer presented with blurred vision and photophobia after receiving pembrolizumab. Ocular findings were bilateral anterior chamber reactions, iris cysts, and macular flecks. Optical coherence tomography (OCT) indicated retinal pigment epithelium (RPE) and ellipsoid-band disruption. Her symptoms subsided with topical steroids but fundal appearance persisted despite cessation of immunotherapies. Similar episodes attacked again with multiple exudative subretinal fluid (SRF) developed after she received pembrolizumab and nivolumab. Steroids could cease anterior chamber reactions while SRF only subsided after discontinuation of immunotherapy. Extensive RPE and ellipsoid-band disruption remained without vision improvements.ConclusionsWe report a rare case of uveitis and retinopathy after immunotherapies with sequent pembrolizumab and nivolumab. A serial change of the maculopathy is demonstrated. Possible ocular toxicities during the treatment course should be considered, and the benefits of continuing the immunotherapy must be weighed against the risks.https://www.frontiersin.org/articles/10.3389/fopht.2022.1021574/fullimmune checkpoint inhibitorspembrolizumabnivolumabovarian canceruveitismaculopathy |
| spellingShingle | Wan-Hua Cho Wei-Yu Chiang Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab Frontiers in Ophthalmology immune checkpoint inhibitors pembrolizumab nivolumab ovarian cancer uveitis maculopathy |
| title | Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| title_full | Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| title_fullStr | Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| title_full_unstemmed | Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| title_short | Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| title_sort | case report serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab |
| topic | immune checkpoint inhibitors pembrolizumab nivolumab ovarian cancer uveitis maculopathy |
| url | https://www.frontiersin.org/articles/10.3389/fopht.2022.1021574/full |
| work_keys_str_mv | AT wanhuacho casereportserialchangesofocularcomplicationsrelatedtoimmunecheckpointinhibitorspembrolizumabandnivolumab AT weiyuchiang casereportserialchangesofocularcomplicationsrelatedtoimmunecheckpointinhibitorspembrolizumabandnivolumab |